EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of PDGF beta receptor binding single domain antibodies conjugated to PET-imaging and therapeutic radionuclides and to target fibrotic stroma in advanced colorectal cancer.
Herman Steen, CEO of BiOrion, “We are delighted with the recognition and support for our PDGF beta receptor binding single domain antibodies targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted imaging diagnostics and therapeutics against fibrotic stroma of solid cancers.”
About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion PET-imaging diagnostics for fibrotic diseases. These diseases include cardiac, hepatic, pulmonary and kidney fibrosis, among many others, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and single domain antibodies that act as targeting vehicles for diagnostic PET radionuclides, therapeutic radionuclides and (existing) anti-fibrotic therapeutics.
For BiOrion Technologies BV:
Herman Steen, PhD
CEO BiOrion Technologies BV